Quantum BioPharma Taps Thermo Fisher to Launch Phase 2 Lucid-MS Trial, Testing Novel Neuroprotective Approach to Multiple Sclerosis

Most multiple sclerosis treatments aim to calm an overactive immune system. A new partnership between Quantum BioPharma (NASDAQ: QNTM) and Thermo Fisher Scientific's clinical research business is advancing a different strategy: shielding the nerve's own protective insulation. The collaboration marks a critical step for a drug candidate that could change how multiple sclerosis is treated.

Quantum BioPharma, a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business. The contract covers implementation of the Phase 2 trial of Lucid-MS, Quantum's lead drug candidate for multiple sclerosis. Thermo Fisher's clinical research business is a leading global contract research organization with deep expertise in central nervous system and MS studies, making it a strong partner to execute this rigorous test.

The significance of this agreement lies in its potential to validate a new therapeutic approach. While existing MS drugs primarily modulate the immune system to reduce relapses, Lucid-MS is designed around a novel neuroprotective mechanism that targets demyelination—the damage to the myelin sheath that insulates nerve fibers. By focusing on protecting myelin rather than solely suppressing immune activity, Lucid-MS could address a root cause of disability progression in MS, offering hope for patients who do not respond adequately to current therapies.

Moving into Phase 2 is a pivotal milestone for any drug candidate. It means the treatment has passed initial safety hurdles and is now being evaluated for efficacy in patients. The involvement of Thermo Fisher's clinical research business adds operational credibility and resources, which can accelerate timelines and improve trial quality. For Quantum BioPharma, this agreement transitions Lucid-MS from planning into execution, a phase where data will begin to show whether the neuroprotective hypothesis holds up in humans.

Investors and industry watchers are paying close attention. Positive Phase 2 results could position Lucid-MS as a first-in-class or best-in-class option in a market dominated by immune-modulating drugs. The MS treatment landscape is large and growing, but many patients still experience disease progression, underscoring the need for therapies with different mechanisms of action. A successful neuroprotective approach could also have implications for other neurodegenerative conditions where demyelination plays a role.

For more details, the full announcement is available via Read More. Additional information about Quantum BioPharma (NASDAQ: QNTM) can be found through Quantum BioPharma (NASDAQ: QNTM), and the latest updates are available in the company's newsroom at https://ibn.fm/QNTM. As with all clinical-stage biopharma investments, risks remain, and forward-looking statements should be considered in light of the company's SEC filings.